<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828581</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-018</org_study_id>
    <nct_id>NCT00828581</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects</brief_title>
  <official_title>An Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the PK properties of lorcaserin in obese or&#xD;
      overweight elderly subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the single-dose pharmacokinetic (PK) parameters of lorcaserin in the obese or overweight Elderly (&gt; 65) to those obtained from the obese or overweight Adult (18-65)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of a single oral dose of lorcaserin in obese or overweight Elderly (&gt; 65) subjects and obese or overweight Adult (18-65) subjects.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lorcaserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorcaserin</intervention_name>
    <arm_group_label>Lorcaserin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females&#xD;
&#xD;
          2. Control (Adult) group: aged between 18 and 65 years (inclusive)&#xD;
&#xD;
          3. Elderly group: aged &gt; 65 years (includes subjects 1 day or more beyond the 65th&#xD;
             birthday)&#xD;
&#xD;
          4. Able to give signed informed consent&#xD;
&#xD;
          5. BMI 27-45 kg/m2, inclusive 6. Eligible male and female subjects must agree not to&#xD;
             participate in a conception process (i.e. active attempt to become pregnant or to&#xD;
             impregnate, egg or sperm donation, in vitro fertilization).&#xD;
&#xD;
          6. Considered to be in stable health in the opinion of the Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior participation in any study of lorcaserin.&#xD;
&#xD;
          2. Clinically significant new illness in the 1 month before screening&#xD;
&#xD;
          3. Not suitable to participate in the study in the opinion of the Investigator including&#xD;
             an existing physical or mental condition that prevents compliance with the protocol&#xD;
&#xD;
          4. History of any of the following cardiovascular conditions:&#xD;
&#xD;
               -  Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG),&#xD;
                  cerebral vascular accident (CVA), transient ischemic attack (TIA) or reversible&#xD;
                  ischemic neurologic deficit (RIND) within 6 months of screening&#xD;
&#xD;
               -  Cardiac arrhythmia requiring initiation of new medical or surgical treatment&#xD;
                  within 6 months of screening (stable medical therapy for &gt; 6 months, pacemakers&#xD;
                  and/or defibrillators implanted &gt; 6 months prior to screening are acceptable)&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  History of pulmonary artery hypertension&#xD;
&#xD;
          5. Positive result of HIV, hepatitis B or hepatitis C screens&#xD;
&#xD;
          6. Initiation of a new prescription medication within 1 month prior to screening with the&#xD;
             following exceptions:&#xD;
&#xD;
          7. Use of SSRIs, SNRIs, and other medications must meet washout period.&#xD;
&#xD;
          8. Participated in any clinical study with an investigational drug, biologic, or device&#xD;
             within 1 month prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRI Worldwide - Lourdes Hospital</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

